Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
BioCardia Announces Pricing of $10 Million Public Offering
12:30pm, Wednesday, 17'th Jun 2020
BioCardia®, Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offer
Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
12:00pm, Friday, 15'th May 2020
SAN CARLOS, Calif., May 15, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
05:40pm, Tuesday, 12'th May 2020
This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
SAN CARLOS, Calif., May 05, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA – Research Report),
BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended
82 Biggest Movers From Yesterday
08:30am, Wednesday, 29'th Apr 2020
Gainers
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares climbed 69.4% to close at $19.50 on Tuesday after the company presented positive preclinical and initial clinical data...
SAN CARLOS, Calif., April 28, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
12:00am, Tuesday, 28'th Apr 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
BioCardia announces litigation financing for Boston Scientific case BCDA;BSX
12:20pm, Tuesday, 14'th Apr 2020
BioCardia announces litigation financing for Boston Scientific case BCDA BSX
BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia Inc.
12:00pm, Tuesday, 14'th Apr 2020
BioCardia®, Inc. (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing wh
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
06:03pm, Thursday, 09'th Apr 2020
SAN CARLOS, Calif., April 09, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
BioCardia (OTCMKTS:BCDA) Rating Reiterated by Maxim Group
08:30am, Sunday, 05'th Apr 2020
Maxim Group reissued their buy rating on shares of BioCardia (OTCMKTS:BCDA) in a research note issued to investors on Wednesday, AnalystRatings.com reports. Maxim Group currently has a $9.00 target pr
